
|Articles|August 26, 2019
ASRS 2019 Street Team: Peter K. Kaiser, MD
Author(s)OT Staff Reports
Dr. Kaiser discusses how risuteganib fared in a phase II trial in patients with intermediate nonexudative AMD.
Advertisement
Peter K. Kaiser, MD, shares the take-home message of his presentation, "Safety and Efficacy of Risuteganib in Intermediate Nonexudative Age-Related Macular Degeneration: First Time Results From a Phase 2 Study." Dr. Kaiser presented at the 2019 annual meeting of the American Society of Retina Specialists.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
SubscribeAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
FDA grants RMAT designation to Emmecell's EO2002 for corneal endothelial disease
2
NeuroOp Guru: What a big data study reveals about NAION and stroke risk
3
Port Delivery System Therapies in Retinal Vascular Diseases
4
Safety Considerations in Retinal Vascular Diseases
5






















